Emtora Biosciences

Emtora Biosciences is a clinical-stage life sciences company developing a novel formulation of rapamycin, eRapa™, for the prevention of cancer onset and recurrence. eRapa™ is a potent mTOR inhibitor believed to offer several significant advantages over rapamycin, including: targeted delivery to active disease sites (in addition to systemic exposure); reduced toxicity and improved tolerability; consistent pharmacokinetics (which may eliminate the need for drug level monitoring); and enhanced bioavailability.